Qionghong Xie

机构：Fudan University, Huashan Hospital · ORCID：0000-0002-6189-2909

发表论文 79 篇 · 总被引 1543 次 · h-index 21

代表论文

• Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy (2024 · Nephrology Dialysis Transplantation · 被引 35)
• Knockout of the C3a receptor protects against renal ischemia reperfusion injury by reduction of NETs formation (2023 · Cellular and Molecular Life Sciences · 被引 33)
• Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease (2023 · Kidney International Reports · 被引 24)
• Matrix protein Tenascin-C promotes kidney fibrosis via STAT3 activation in response to tubular injury (2022 · Cell Death and Disease · 被引 23)
• Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China (2024 · Renal Failure · 被引 14)
• Target Antigens of Membranous Nephropathy With Syphilis Infection (2023 · Kidney International Reports · 被引 11)